|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
|
WO1997009976A2
(en)
|
1995-09-01 |
1997-03-20 |
Washington University |
Method of reducing neurotoxic injury with zinc chelators
|
|
PL329070A1
(en)
|
1996-03-22 |
1999-03-15 |
Du Pont Pharm Co |
Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques
|
|
CN100525766C
(zh)
|
1997-06-02 |
2009-08-12 |
詹森药业有限公司 |
用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物
|
|
WO1999004794A1
(en)
|
1997-07-25 |
1999-02-04 |
Merck & Co., Inc. |
Cyclic amine modulators of chemokine receptor activity
|
|
EP1031563B1
(en)
|
1997-09-30 |
2005-12-28 |
Daiichi Pharmaceutical Co., Ltd. |
Sulfonyl derivatives
|
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
|
US6172061B1
(en)
|
1997-12-19 |
2001-01-09 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
|
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
|
BR0010655A
(pt)
|
1999-03-24 |
2002-02-13 |
Anormed Inc |
Compostos heterocìclicos para ligação ao receptor de quimiocina
|
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
|
US6602872B1
(en)
|
1999-12-13 |
2003-08-05 |
Merck & Co., Inc. |
Substituted pyridazines having cytokine inhibitory activity
|
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
PT1317451E
(pt)
|
2000-09-15 |
2006-12-29 |
Anormed Inc |
Compostos heterocíclicos que se ligam a receptores de quimioquinas
|
|
US6835731B2
(en)
|
2000-09-15 |
2004-12-28 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds
|
|
CA2419224A1
(en)
|
2000-09-15 |
2002-03-21 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds
|
|
MXPA03005152A
(es)
|
2000-12-11 |
2004-10-14 |
Tularik Inc |
Antogonista de cxcr3.
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
ES2380009T3
(es)
|
2001-07-31 |
2012-05-07 |
Genzyme Global S.A.R.L. |
Métodos para movilizar las células madre/progenitoras
|
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
|
WO2003022785A2
(en)
|
2001-09-12 |
2003-03-20 |
Anormed Inc. |
Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
|
|
CA2467718C
(en)
|
2001-12-21 |
2011-04-26 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
|
WO2004019973A1
(en)
|
2002-08-14 |
2004-03-11 |
Atugen Ag |
Use of protein kinase n beta
|
|
WO2004052862A1
(ja)
|
2002-12-10 |
2004-06-24 |
Ono Pharmaceutical Co., Ltd. |
含窒素複素環化合物およびその医薬用途
|
|
KR20070087266A
(ko)
|
2003-04-03 |
2007-08-28 |
세마포르 파머슈티컬즈, 아이엔씨. |
피아이-3 키나아제 억제제 프로드러그
|
|
EP1613613B1
(en)
|
2003-04-11 |
2021-06-02 |
Genzyme Corporation |
Cxcr4 chemokine receptor binding compounds
|
|
US7501518B2
(en)
*
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
|
AU2004232361A1
(en)
|
2003-04-22 |
2004-11-04 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
CN1777423A
(zh)
*
|
2003-04-22 |
2006-05-24 |
阿诺麦德股份有限公司 |
具有促进功效的趋化因子受体结合的杂环化合物
|
|
CN1832939B
(zh)
|
2003-05-30 |
2010-04-28 |
杰明X医药品加拿大公司 |
用于治疗癌症或病毒病的三杂环化合物、组合物和方法
|
|
US7173015B2
(en)
|
2003-07-03 |
2007-02-06 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
|
CN1930127B
(zh)
|
2004-03-15 |
2012-11-21 |
阿诺麦德股份有限公司 |
用于合成cxcr4拮抗剂的方法
|
|
EP1742936A2
(en)
|
2004-04-13 |
2007-01-17 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
|
DE102004021716A1
(de)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
|
|
SI2612862T1
(sl)
|
2004-05-13 |
2017-04-26 |
Icos Corporation |
Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
|
|
US20080096861A1
(en)
|
2004-08-02 |
2008-04-24 |
Smithkline Beecham Corporation |
Chemical Compounds
|
|
CA2577100A1
(en)
|
2004-08-16 |
2006-03-02 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
JP2008511669A
(ja)
|
2004-09-02 |
2008-04-17 |
スミスクライン ビーチャム コーポレーション |
化合物
|
|
WO2006036816A2
(en)
|
2004-09-24 |
2006-04-06 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
US20090093454A1
(en)
|
2005-03-04 |
2009-04-09 |
Kristjan Gudmundsson |
Chemical Compounds
|
|
EP1888550B1
(en)
|
2005-05-12 |
2014-06-25 |
AbbVie Bahamas Ltd. |
Apoptosis promoters
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20090203533A1
(en)
|
2005-07-08 |
2009-08-13 |
Siemens Medicals Solutions Diagnositcs Gmbh |
Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
|
|
US20080214562A1
(en)
*
|
2005-07-11 |
2008-09-04 |
Kristjan Gudmundsson |
Chemical Compounds
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
WO2007015074A1
(en)
|
2005-08-02 |
2007-02-08 |
Ineos Europe Limited |
Diene polymerisation
|
|
CA2619828A1
(en)
|
2005-08-19 |
2007-02-22 |
Genzyme Corporation |
Methods to enhance chemotherapy
|
|
EP1919872A4
(en)
|
2005-08-31 |
2009-08-05 |
Smithkline Beecham Corp |
CHEMICAL COMPOUNDS
|
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
|
CN103626742B
(zh)
|
2005-11-01 |
2017-04-26 |
塔格根公司 |
激酶的联-芳基间-嘧啶抑制剂
|
|
WO2007058322A1
(ja)
|
2005-11-18 |
2007-05-24 |
Ono Pharmaceutical Co., Ltd. |
塩基性基を含有する化合物およびその用途
|
|
US20070123538A1
(en)
|
2005-11-30 |
2007-05-31 |
Schering Corporation |
Compositions comprising a combination of CCR5 and CXCR4 antagonists
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
PE20070946A1
(es)
|
2006-01-25 |
2007-10-16 |
Smithkline Beecham Corp |
COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
|
|
JP2009524689A
(ja)
|
2006-01-25 |
2009-07-02 |
スミスクライン ビーチャム コーポレーション |
化合物
|
|
GB0605786D0
(en)
*
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
|
MX2008013578A
(es)
|
2006-04-26 |
2009-03-23 |
Hoffmann La Roche |
Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
|
|
CN101466376A
(zh)
|
2006-06-12 |
2009-06-24 |
辉瑞产品公司 |
用于提高免疫重建并治疗hiv患者的机会感染的ccr5拮抗剂
|
|
TWI482772B
(zh)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
US20100298314A1
(en)
|
2006-12-20 |
2010-11-25 |
Schering Corporation |
Novel jnk inhibitors
|
|
HRP20151386T1
(hr)
|
2007-03-12 |
2016-02-26 |
Ym Biosciences Australia Pty Ltd |
Fenil aminopirimidinski spojevi i njihova primjena
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
EP1974729A1
(en)
|
2007-03-28 |
2008-10-01 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
|
|
CN101855222A
(zh)
|
2007-05-10 |
2010-10-06 |
通用电气健康护理有限公司 |
对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US20110070657A1
(en)
|
2007-08-17 |
2011-03-24 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
|
EP2036556A1
(en)
|
2007-09-12 |
2009-03-18 |
Heinrich-Pette-Institut |
Piperidone derivatives and medical uses thereof
|
|
US9101628B2
(en)
|
2007-09-18 |
2015-08-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and composition of treating a flaviviridae family viral infection
|
|
CA2709883A1
(en)
|
2007-12-19 |
2009-06-25 |
The Scripps Research Institute |
Benzimidazoles and analogs as rho kinase inhibitors
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
CN102088993A
(zh)
|
2008-03-20 |
2011-06-08 |
卡罗勒斯治疗公司 |
炎症的治疗方法
|
|
AU2009228034A1
(en)
|
2008-03-28 |
2009-10-01 |
Altiris Therapeutics |
Chemokine receptor modulators
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP2010016628A
(ja)
*
|
2008-07-03 |
2010-01-21 |
Canon Inc |
画像処理装置及び画像処理方法
|
|
ES2467108T3
(es)
|
2008-12-09 |
2014-06-11 |
Gilead Sciences, Inc. |
Moduladores de receptores tipo toll
|
|
EP2482805B1
(en)
|
2009-09-28 |
2014-11-19 |
Zenbury International Limited |
Pharmaceutical composition
|
|
US20110293686A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
|
US9155723B2
(en)
|
2010-06-28 |
2015-10-13 |
The General Hospital Corporation |
Anti-CXCR4 as a sensitizer to cancer therapeutics
|
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
|
US9267934B2
(en)
|
2010-10-26 |
2016-02-23 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
|
EP3153510B1
(en)
|
2010-12-03 |
2020-05-06 |
Emory University |
Fused azines as chemokine cxcr4 receptor modulators and uses related thereto
|
|
JP6076913B2
(ja)
|
2010-12-07 |
2017-02-08 |
ドレクセル ユニバーシティ |
癌からの転移を阻害する方法
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN103476410B
(zh)
|
2011-01-11 |
2020-02-21 |
戴麦里克斯生物科学有限公司 |
联合疗法
|
|
RU2638802C2
(ru)
|
2011-05-16 |
2017-12-15 |
Джензим Корпорейшн |
Применение антагонистов cxcr4
|
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
JP2015503624A
(ja)
|
2012-01-12 |
2015-02-02 |
ギリアード サイエンシーズ， インコーポレイテッド |
医薬組成物およびその調製方法
|
|
EP2922861A4
(en)
|
2012-11-26 |
2016-09-14 |
Caris Life Sciences Switzerland Holdings Gmbh |
BIOMARKER COMPOSITIONS AND METHODS
|
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
|
WO2014197680A1
(en)
|
2013-06-05 |
2014-12-11 |
Salk Institute For Biological Studies |
Vitamin d receptor agonists to treat diseases involving cxcl12 activity
|
|
CA2920377A1
(en)
|
2013-08-05 |
2015-02-12 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
|
EA201690473A1
(ru)
|
2013-08-27 |
2017-03-31 |
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи |
Комбинированный состав двух противовирусных соединений
|
|
CA3206628A1
(en)
|
2013-09-12 |
2015-03-19 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
|
KR20160093012A
(ko)
|
2013-11-05 |
2016-08-05 |
코그네이트 바이오서비시즈, 인코포레이티드 |
암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
|
|
WO2015143092A1
(en)
|
2014-03-18 |
2015-09-24 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
|
NZ724368A
(en)
|
2014-03-19 |
2023-07-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
EP3157921A1
(en)
|
2014-06-23 |
2017-04-26 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
|
|
DK3169341T3
(da)
|
2014-07-16 |
2019-08-05 |
Transgene Sa |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
SG11201704756YA
(en)
|
2014-12-12 |
2017-07-28 |
Commw Scient Ind Res Org |
Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
EP3307778A1
(en)
|
2015-06-12 |
2018-04-18 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
|
EP4585268A3
(en)
|
2015-09-14 |
2025-10-15 |
Twelve Therapeutics, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
|
WO2017106332A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
CN109069426B
(zh)
|
2015-12-14 |
2021-10-29 |
X4 制药有限公司 |
治疗癌症的方法
|
|
PL3393468T3
(pl)
|
2015-12-22 |
2023-01-23 |
X4 Pharmaceuticals, Inc. |
Metody leczenia niedoboru odporności
|
|
CA3010617A1
(en)
|
2016-01-22 |
2017-07-27 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
ES3014978T3
(en)
|
2016-04-14 |
2025-04-28 |
Creatv Microtech Inc |
Methods of using pd-l1 expression in treatment decisions for cancer therapy
|
|
WO2017223243A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
CN109640988A
(zh)
*
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
JP2020525427A
(ja)
|
2017-06-21 |
2020-08-27 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
癌を処置するための方法
|
|
US20210349099A1
(en)
|
2017-11-07 |
2021-11-11 |
X4 Pharmaceuticals, Inc. |
Cancer biomarkers and methods of use thereof
|
|
WO2019126106A1
(en)
|
2017-12-19 |
2019-06-27 |
X4 Pharmaceuticals, Inc. |
Acyclic cxcr4 inhibitors and uses thereof
|
|
JP2021521439A
(ja)
|
2018-04-13 |
2021-08-26 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
がん血清バイオマーカーおよびその使用方法
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|